Potential Treatment of Steroid-Resistant Alopecia Areata Using Allogeneic Exosomes Derived From Adipose Tissue Mesenchymal Stromal Cells: A Case Report.
Kianpisheh M., Piroozhashemi M., Feshangchian-Atashbar S., Ghamari A., Shoae-Hassani A.
Laboratory Study on Hair Loss, Chronic Inflammation, Autoimmune Research, published in Clin Case Rep (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Clin Case Rep (2026)
- Country
- England
- Reported sample size
- —
- PMID
- 42466009
- DOI
- 10.1002/ccr3.73176
Abstract (original English)
A 31-year-old man with severe, corticosteroid-resistant alopecia areata presented with substantial scalp hair loss (Severity of Alopecia Tool [SALT] score: 60%) despite a 1-year regimen of topical corticosteroids, 5% minoxidil, and oral prednisolone. He was treated with allogeneic exosomes derived from adipose tissue mesenchymal stromal cells (ADMSCs-Exo) at 3-week intervals over 12 weeks (four sessions; 10 12 particles each). A cessation of hair shedding was noted after the initial session, followed by progressive regrowth that led to near-complete hair restoration by Week 12. Treatment was accompanied by an increase in anti-inflammatory cytokines (IL-4, IL-6, IL-10) and a reduction of IFN-γ, TNF-α, and IL-17 toward baseline levels. No adverse effects were reported during active treatment or throughout the 18-week posttreatment follow-up period. While limited to a single patient, this case suggests that ADMSC-derived exosomes warrant further investigation as a potential cell-free therapeutic option for refractory alopecia areata.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence comes from animal or laboratory studies and has not been confirmed in humans.
How we grade evidenceRelated research
- Level ASystematic Review
Exosomes in trichology: A literature review.
Systematic Review on Hair Loss, Hair Regeneration, published in JPRAS Open (2026) — summary generated from the PubMed abstract.
- 2026
JPRAS Open - Level ASystematic Review
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Systematic Review with a reported sample of 724 on Hair Loss, Hair Regeneration, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 724
Stem Cell Res Ther - Level ASystematic Review
Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources.
Systematic Review on Hair Loss, Hair Regeneration, published in Clin Cosmet Investig Dermatol (2025) — summary generated from the PubMed abstract.
- 2025
Clin Cosmet Investig Dermatol - Level ASystematic Review
Autologous Stem Cell-derived Therapies for Androgenetic Alopecia: A Systematic Review of Randomized Control Trials on Efficacy, Safety, and Outcomes.
Systematic Review on Hair Loss, Hair Regeneration, Immune Modulation, published in Plast Reconstr Surg Glob Open (2024) — summary generated from the PubMed abstract.
- 2024
Plast Reconstr Surg Glob Open - Level ASystematic Review
Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials.
Systematic Review with a reported sample of 2888 on Chronic Wound, Scar, Hair Loss, published in Stem Cell Res Ther (2024) — summary generated from the PubMed abstract.
- 2024
- n = 2888
Stem Cell Res Ther - Level ASystematic Review
Systematic review of exosome treatment in hair restoration: Preliminary evidence, safety, and future directions.
Systematic Review on Hair Loss, Hair Regeneration, published in J Cosmet Dermatol (2023) — summary generated from the PubMed abstract.
- 2023
J Cosmet Dermatol